Goldberg Law PC, a national shareholder rights litigation firm, announces a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company”) (NYSE: TARO). Investors who purchased or otherwise acquired shares between July 3, 2014 and September 9, 2016 inclusive (the “Class Period”) are encouraged to contact the firm in advance of the December 27, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The complaint alleges that during the Class Period, Taro made false and/or misleading statements and/or failed to disclose that: since 2014 the Company has worked with other pharmaceutical companies to keep the price of generic products artificially high; that the foregoing behavior violated federal antitrust laws; that Taro’s revenues during the Class Period were the result of illegal conduct; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.

On September 9, 2016, Taro announced that its subsidiary and two senior officers received grand jury subpoenas from the U.S. Department of Justice, Antitrust Division, seeking documents regarding the sale of generic pharmaceutical products. When this news was announced, shares of Taro fell in value. On October 17, 2016, NECA-IBEW Welfare Trust Fund filed an antitrust class action lawsuit against Taro and several other pharmaceutical companies alleging involvement in the price-fixing of Clobetasol since 2014.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.